IP Library Granted Patent US 10,035,845
Granted Patent B2
US 10,035,845 · App. 15/661,867 · Granted Jul 31, 2018

Neutralizing antibodies to HIV-1 and their use

Inventors: John Mascola (Rockville, MD); Richard Wyatt (San Diego, CA); Xueling Wu (Potomac, MD); Yuxing Li (Boyds, MD); Carl-Magnus Hogerkorp (Vellinge, SE); Mario Roederer (Washington, DC); Zhi-yong Yang (Potomac, MD); Gary Nabel (Cambridge, MA); Peter Kwong (Washington, DC); Tongqing Zhou (Boyds, MD); Mark Connors (Bethesda, MD); William Schief (Encinitas, CA)
Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; University of Washington
C07K16/1063A61K39/42A61K45/06C07K2317/565C07K2317/76C07K2317/92C12N2740/10011C12N2740/16011C12N2740/16111
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,035,845
App. No.
15/661,867
Granted
Jul 31, 2018
Kind
B2
Abstract

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

Claims (35)

1. An isolated nucleic acid molecule, comprising:

a nucleotide sequence encoding:

an antibody heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively;

an antibody light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; or

an antibody comprising a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively, and an antibody light chain variable region comprising a LCDR1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively, wherein the antibody specifically binds to gp120.

2. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1.

3. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

4. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 3.

5. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 4.

6. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1.

7. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the LCDR1, the LCDR2, and the LCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 2.

8. The isolated nucleic acid molecule of claim 1 , comprising:

the nucleotide sequence encoding the antibody comprising

the heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively, and

the antibody light chain variable region comprising a LCDR1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and

wherein the antibody specifically binds to gp120.

9. The isolated nucleic acid molecule of claim 1 , wherein

the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1; and

the light chain variable region comprises the LCDR1, the LCDR2, and the LCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 2.

10. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2.

11. The isolated nucleic acid molecule of claim 10 , wherein the antibody is an IgG, an IgM, or an IgA.

12. The isolated nucleic acid molecule of claim 11 , wherein the antibody is an IgG 1.

13. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding an antigen binding fragment of the antibody encoded by the nucleic acid molecule of claim 8 .

14. The isolated nucleic acid molecule of claim 13 , wherein the antigen binding fragment is a Fab fragment, a Fab′ fragment, a F(ab)′ 2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv).

15. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid sequence comprises at least one of one of the nucleic acid sequences set forth as SEQ ID NOs: 29-32.

16. The isolated nucleic acid molecule of claim 1 , operably linked to a promoter.

17. An expression vector comprising the isolated nucleic acid molecule of claim 1 .

18. The expression vector of claim 17 , wherein the expression vector is a viral vector.

19. The expression vector of claim 18 , wherein the viral vector is an adeno-associated viral vector.

20. An isolated host cell transformed with the nucleic acid molecule of claim 1 .

21. A method of making an antibody that specifically binds to gp120, comprising:

expressing in a host cell one or more nucleic acid molecules encoding:

an antibody heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively; and

an antibody light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and

purifying the antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: MASCOLA, JOHN R.; WU, XUELING; LI, YUXING; ROEDERER, MARIO; YANG, ZHI-YONG; NABEL, GARY; KWONG, PETER; ZHOU, TONGQING; CONNORS, MARK; OFEK, GILAD; SHAPIRO, LAWRENCE; ZHU, JIANG; WYATT, RICHARD; HOGERKORP, CARL-MAGNUS
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 043122/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: SCHIEF, WILLIAM R.
To: UNIVERSITY OF WASHINGTON
Reel/Frame 043122/0225 →
Continuity (9)
Division 14864705 · Sep 24, 2015
Division 13498125
Provisional Application 61385531 · Sep 22, 2010
Provisional Application 61402314 · Aug 27, 2010
Provisional Application 61346808 · May 20, 2010
Provisional Application 61290135 · Dec 24, 2009
Provisional Application 61252613 · Oct 16, 2009
Provisional Application 61246039 · Sep 25, 2009
Related Publication 20170369558A1 · Dec 28, 2017